Due to earlier detection by prostate-specific antigen (PSA) testing and advances in treatment, the mortality of PCa rapidly declined by 52% from 1993 to 2015 (Siegel et al., 2018). The gene discussed is KLK3; the disease is posterior cortical atrophy.